P Panaccio, T Grottola, M Ricciardiello, P di Sebastiano and F F di Mola
S S Annunziata Hospital, Italy D Annunzio University of Chieti�Pescara, Italy
Posters & Accepted Abstracts: Arch Cancer Res
Aim: Splenic flexure (SF) cancer represents is a not common condition and its treatment is still under debate. Laparoscopic surgery is nowadays well accepted for treatment of colon cancer at any stages; however complete mesocolic excision (CME) using laparoscopic ap-proach for SF cancer remains technical demanding. The aim of this study is to prove the safeness and feasibility of the minimally invasive splenic flexure resection for cancer. Methods: We present a single-institution experience of laparoscopic CME for SF cancer. In-traoperative, pathologic, and postoperative data of patients who underwent laparoscopic SF resection were reviewed to assess technical feasibility and oncologic safety. Technical feature, histopathology, morbidity and mortality were evaluated. Results: From February 2015 to September 2017 a minimally invasive approach was proposed to 20 patients (M/F 14/6) affected by splenic flexure cancer. In all patients the procedure was completed by laparoscopy. The anastomosis was completed intracorporeal in 95% of the cases. The distal margin was 3.2±2.5 cm and the proximal margin was 6.5±3.2 cm from the tumor site. The mean number of harvested nodes was 13.4±6.1. The mean operative time was 224.8±38 min, and the blood loss was 80±27 ml. In one case a laparoscopic partial gastrectomy was associated due to tumor invasion. In addition, a laparoscopic subtotal colec-tomy was performed in another case due to a synchronous right side tumor. Mean post-operative stay was 6.8 days. Readmission was necessary for two patients: in one case due to persistent abdominal pain and medically treated and in a second case due to abdominal fluid collection that was treated by percutaneous drainage. No major morbidity was recorded. Conclusion: Laparoscopic SF resection with CME is feasible and safe for the treatment of early-stage and locally advanced SF cancer.
E-mail:
paolo.panaccio@gmail.com